Children are among the NHS patients being denied access to revolutionary cancer drugs as a result of red tape and extra costs caused by Brexit, according to a report leaked to the Guardian.
Two examples illustrate how the UK’s departure from the EU is derailing UK cancer research, leaving patients in limbo and unable to access pioneering treatments.
eSMART is a trial of new targeted drugs and chemotherapy for children, teenagers and young adults whose cancer has returned or treatment has stopped working.
